Long‐term outcomes in children with riboflavin transporter deficiency and surveillance recommendations
Developmental Medicine & Child Neurology · 2025
DOI: 10.1111/dmcn.16083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Medicine & Child Neurology, 2025. Verfasst von Jack R Fennessy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, University of Sydney School of Health Sciences, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Riboflavin, Membrane Transport Proteins, Hearing Loss, Sensorineural. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, Cure RTD Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
The aim of this longitudinal case series was to describe long‐term functional outcome in a group of individuals with riboflavin transporter deficiency (RTD) treated with high‐dose oral riboflavin. Data were collected between 2012 to 2022. Eleven individuals with RTD were assessed at 12‐month intervals for monitoring of disease progression. Patients had commenced high‐dose oral riboflavin from the time of genetic diagnosis. Individuals for whom riboflavin supplementation was initiated early after disease onset had better outcomes compared to those in whom diagnosis was delayed. Despite ongoing riboflavin supplementation, the Charcot–Marie–Tooth disease Pediatric Scale (CMTPedS) total score and the subitems of balance and the 6‐Minute Walk Test distance as well as respiratory function worsened, while grip strength improved. There was evidence of improvement in hearing loss and optic atrophy limited to the first 12 months of treatment. While treatment with riboflavin slowed disease progression, patients were left with residual disability. To track disease progression and response to riboflavin supplementation over time, we recommend using the RTD Pediatric Scale and provide a list of clinical measures for regular surveillance of children with RTD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Health, University of Sydney School of Health Sciences, Sydney, New South Wales, Australia.
- Paediatric Gait Analysis Service of New South Wales, Sydney Children's Hospitals Network, Westmead, New South Wales, Australia.
- Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- TY Nelson Department of Neurology and Neurosurgery, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
ORCID-Profile: Jack R Fennessy, Kayla M D Cornett, Gabrielle A Donlevy, Marnee J Mckay, Manoj P Menezes
Förderung
- NINDS NIH HHS
- Cure RTD Foundation
Zitieren
APA
Fennessy, J. R., Cornett, K. M. D., Donlevy, G. A., Mckay, M. J., Burns, J., & Menezes, M. P. (2025). Long‐term outcomes in children with riboflavin transporter deficiency and surveillance recommendations. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.16083
Vancouver
Fennessy JR, Cornett KMD, Donlevy GA, Mckay MJ, Burns J, Menezes MP. Long‐term outcomes in children with riboflavin transporter deficiency and surveillance recommendations. Developmental Medicine & Child Neurology. 2025. doi:10.1111/dmcn.16083
BibTeX
@article{Fennessy2025,
author = {Fennessy, Jack R and Cornett, Kayla M D and Donlevy, Gabrielle A and Mckay, Marnee J and Burns, Joshua and Menezes, Manoj P},
title = {Long‐term outcomes in children with riboflavin transporter deficiency and surveillance recommendations},
journal = {Developmental Medicine & Child Neurology},
year = {2025},
doi = {10.1111/dmcn.16083}
}
EUVIMED